Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 477

1.

GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.

Lu S, Gao Y, Huang X, Wang X.

Int J Oncol. 2014 Apr;44(4):1259-67. doi: 10.3892/ijo.2014.2305. Epub 2014 Feb 14.

PMID:
24535538
2.

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.

Mol Cancer. 2014 Jan 13;13:7. doi: 10.1186/1476-4598-13-7.

3.

Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.

Zhao J, Lin W, Cao Z, Liu L, Zhuang Q, Zhong X, Hong Z, Peng J.

Oncol Rep. 2013 Sep;30(3):1309-14. doi: 10.3892/or.2013.2585. Epub 2013 Jul 3.

PMID:
23828071
4.

Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.

Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Sethi G.

J Cell Physiol. 2012 May;227(5):2184-95. doi: 10.1002/jcp.22954.

PMID:
21792937
5.
6.

SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.

Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Epub 2012 Sep 25. Erratum in: Cancer Sci. 2013 Oct;104(10):1389.

7.

Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.

Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q, Cao P.

Cancer Lett. 2013 Jan 28;328(2):243-51. doi: 10.1016/j.canlet.2012.09.019. Epub 2012 Sep 29.

PMID:
23032719
8.

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.

Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.

Cancer Lett. 2014 Dec 1;355(1):96-105. doi: 10.1016/j.canlet.2014.09.011. Epub 2014 Sep 11.

PMID:
25218350
9.

HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.

Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.

Cancer Lett. 2012 Mar 28;316(2):187-95. doi: 10.1016/j.canlet.2011.10.037. Epub 2011 Nov 4.

PMID:
22182943
10.

Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.

Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, Aggarwal BB.

Clin Cancer Res. 2007 May 15;13(10):3024-32.

11.

Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.

Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G.

Br J Pharmacol. 2013 Oct;170(4):807-21. doi: 10.1111/bph.12302.

12.

Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.

Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, Shanmugam MK, Dai X, Li F, Deivasigamani A, Hui KM, Kumar AP, Lobie PE, Bender A, Basappa, Sethi G, Rangappa KS.

J Biol Chem. 2014 Dec 5;289(49):34296-307. doi: 10.1074/jbc.M114.601104. Epub 2014 Oct 15.

13.
14.

The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo.

Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK, Deng LW.

PLoS One. 2011;6(6):e21077. doi: 10.1371/journal.pone.0021077. Epub 2011 Jun 20.

15.

Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.

Zeng KW, Li N, Dong X, Ma ZZ, Jiang Y, Jin HW, Tu PF.

Eur J Pharmacol. 2013 Aug 15;714(1-3):261-73. doi: 10.1016/j.ejphar.2013.04.026. Epub 2013 May 15.

PMID:
23684542
16.

Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.

Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS.

Cancer Lett. 2013 Jan 1;328(1):176-87. doi: 10.1016/j.canlet.2012.08.005. Epub 2012 Aug 15.

PMID:
22902995
18.

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.

Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D, Pan S, Liu J, Jiang H, Liu L.

Mol Cancer. 2013 Oct 5;12(1):114. doi: 10.1186/1476-4598-12-114.

19.

Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.

Zhao J, Chen X, Lin W, Wu G, Zhuang Q, Zhong X, Hong Z, Peng J.

Int J Oncol. 2013 Mar;42(3):971-8. doi: 10.3892/ijo.2013.1779. Epub 2013 Jan 18.

PMID:
23338043
20.

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.

Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O.

BMC Cancer. 2008 Jul 23;8:206. doi: 10.1186/1471-2407-8-206.

Supplemental Content

Support Center